Viagra is usually filed under one very specific use, but fresh research is putting a much bigger spotlight on the drug’s active ingredient. Scientists say sildenafil may do more than improve blood flow, with early evidence pointing to a possible role in slowing how cancer spreads.
The medication has been around for years and is best known for treating erectile dysfunction. It was originally developed for high blood pressure and chest pain tied to poor blood flow, then turned heads when its effect on sexual function showed up during clinical testing.
Now, a study linked to the American Association for Cancer Research suggests the pill may have a surprising edge against metastasis, the process that allows cancer cells to break away from a primary tumor and travel to distant parts of the body. That kind of spread is often what turns cancer into a far more dangerous disease.
Researchers at the Weizmann Institute of Science in Israel, working with scientists from the U.S. National Cancer Institute, looked at human and mouse cancer cells, genetics, and a massive set of health records from Clalit Health Services. The scope mattered because it gave the team a broad look at how sildenafil interacts with cells, proteins, fats, cholesterol and energy pathways all at once.
The central finding was intriguing: sildenafil appears to interfere with a cancer cell’s ability to use cholesterol. Since cholesterol helps power important cellular activity, cutting off that supply may make it harder for cancer cells to detach and move through the body.
The drug works by blocking phosphodiesterase type 5, or PDE5, which raises levels of cGMP. That same mechanism is part of what makes Viagra effective for erectile dysfunction, because it helps blood vessels relax and widen.
But the cancer angle goes deeper. According to the researchers, cGMP also interacts with a protein that shuttles cholesterol inside cells, reducing the amount available for the kind of activity cancer cells need to survive and spread. The team said those cells seem especially sensitive when cholesterol supply drops.
The study also raises the possibility that Viagra-family drugs could one day be paired with statins, which are already used to reduce cholesterol production. That combination, in theory, could squeeze tumor cells from two sides by limiting both stored and newly made cholesterol.
Dr. Yarden Ariav and senior researcher Ayelet Erez said the work points to a new biological pathway that connects a familiar signaling molecule to cholesterol control inside cells. The message is simple but powerful: cancer behavior is not only about mutations inside a tumor, but also about the body’s wider chemical environment.
That broader view matters because it may change how doctors think about treatment. If a patient is already taking medications for unrelated conditions, those drugs could end up influencing cancer biology in ways nobody expected.
Still, the findings are not a green light to start repurposing the pill on the spot. The mouse data may not translate cleanly to people, and the human evidence is observational, which means it shows a connection but not proof that sildenafil directly causes the effect.
Even with those limits, the work adds a jolt of energy to the conversation around drug repurposing. A medicine built for one purpose may be carrying hidden potential in another arena, and that kind of surprise tends to keep researchers looking a lot harder at old familiar pills.
